Thomas M. Siler

1.5k total citations
24 papers, 549 citations indexed

About

Thomas M. Siler is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Thomas M. Siler has authored 24 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 16 papers in Physiology and 1 paper in Pediatrics, Perinatology and Child Health. Recurrent topics in Thomas M. Siler's work include Chronic Obstructive Pulmonary Disease (COPD) Research (23 papers), Asthma and respiratory diseases (16 papers) and Respiratory Support and Mechanisms (12 papers). Thomas M. Siler is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (23 papers), Asthma and respiratory diseases (16 papers) and Respiratory Support and Mechanisms (12 papers). Thomas M. Siler collaborates with scholars based in United States, United Kingdom and South Africa. Thomas M. Siler's co-authors include Alison Church, Edward Kerwin, Gregory Feldman, Alison Donald, Alpha A. Fowler, James E. Swierkosz, Thomas M. Hyers, Robert O. Webster, Benjamin Krämer and Roger Owen and has published in prestigious journals such as PLoS ONE, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Thomas M. Siler

21 papers receiving 530 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas M. Siler United States 10 501 381 31 26 22 24 549
Sümeyye Alparslan Bekir Türkiye 5 223 0.4× 248 0.7× 58 1.9× 29 1.1× 19 0.9× 14 352
Leon S. Greos United States 9 184 0.4× 214 0.6× 19 0.6× 19 0.7× 21 1.0× 13 329
Ai Higashi Japan 7 138 0.3× 245 0.6× 33 1.1× 48 1.8× 6 0.3× 13 329
Alison Church United States 20 1.4k 2.9× 1.3k 3.3× 18 0.6× 23 0.9× 23 1.0× 43 1.5k
Brett Haumann United States 17 728 1.5× 673 1.8× 32 1.0× 5 0.2× 19 0.9× 37 830
Naveen Kumar Bhatraju India 7 79 0.2× 88 0.2× 47 1.5× 23 0.9× 30 1.4× 17 193
Anna Unseld Germany 9 297 0.6× 371 1.0× 59 1.9× 4 0.2× 27 1.2× 19 499
José Pedro Almeida Portugal 10 65 0.1× 102 0.3× 41 1.3× 10 0.4× 25 1.1× 19 216
Li-Jun Ma China 10 330 0.7× 122 0.3× 75 2.4× 20 0.8× 16 0.7× 16 426
Gabriele Stöhr 2 263 0.5× 31 0.1× 27 0.9× 7 0.3× 41 1.9× 3 330

Countries citing papers authored by Thomas M. Siler

Since Specialization
Citations

This map shows the geographic impact of Thomas M. Siler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas M. Siler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas M. Siler more than expected).

Fields of papers citing papers by Thomas M. Siler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas M. Siler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas M. Siler. The network helps show where Thomas M. Siler may publish in the future.

Co-authorship network of co-authors of Thomas M. Siler

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas M. Siler. A scholar is included among the top collaborators of Thomas M. Siler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas M. Siler. Thomas M. Siler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anzueto, Antonio, Igor Barjaktarević, Thomas M. Siler, et al.. (2023). Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). American Journal of Respiratory and Critical Care Medicine. 208(4). 406–416. 67 indexed citations
2.
Siler, Thomas M., et al.. (2023). POOLED SAFETY RESULTS OVER 24 WEEKS FROM THE ENHANCE PROGRAM WITH ENSIFENTRINE, A NOVEL DUAL PHOSPHODIESTERASE (PDE) 3 AND 4 INHIBITOR. CHEST Journal. 164(4). A4981–A4983. 2 indexed citations
3.
Criner, Gerard J., David Halpin, MeiLan K. Han, et al.. (2022). Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respiratory Medicine. 205. 107040–107040. 6 indexed citations
4.
Siler, Thomas M., et al.. (2022). Correct use and ease-of-use of placebo ELLIPTA dry-powder inhaler in adult patients with chronic obstructive pulmonary disease. PLoS ONE. 17(8). e0273170–e0273170. 2 indexed citations
5.
Siler, Thomas M., et al.. (2021). Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD. Pulmonary Therapy. 7(2). 503–516.
6.
Siler, Thomas M., Edmund J. Moran, Chris N. Barnes, & Glenn Crater. (2020). Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 7(2). 99–106. 8 indexed citations
7.
Siler, Thomas M., et al.. (2019). TOLERABILITY AND EFFICACY OF REVEFENACIN WHEN ADMINISTERED WITH FORMOTEROL VIA NEBULIZATION. CHEST Journal. 156(4). A1160–A1161. 1 indexed citations
8.
Kerwin, Edward, Thomas M. Siler, Samir Arora, et al.. (2018). Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD. International Journal of COPD. Volume 13. 1483–1494. 2 indexed citations
9.
Martínez, Fernando J., Klaus F. Rabe, Gary T. Ferguson, et al.. (2016). Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. CHEST Journal. 151(2). 340–357. 94 indexed citations
10.
Siler, Thomas M., Atsushi Nagai, Catherine Scott-Wilson, Dawn Midwinter, & Courtney Crim. (2016). A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respiratory Medicine. 123. 8–17. 18 indexed citations
11.
Siler, Thomas M., Alison Donald, Dianne M. O’Dell, Alison Church, & William A. Fahy. (2016). A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 µg on health-related quality of life in patients with COPD. International Journal of COPD. 11. 971–971. 28 indexed citations
12.
Kerwin, Edward, Thomas M. Siler, Phillip E. Korenblat, et al.. (2016). Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 3(2). 549–559. 14 indexed citations
13.
14.
15.
Siler, Thomas M., et al.. (2015). Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies. COPD Journal of Chronic Obstructive Pulmonary Disease. 13(1). 1–10. 48 indexed citations
16.
17.
Siler, Thomas M., Craig LaForce, Farid Kianifard, Selwyn Spangenthal, & James Williams. (2014). Once-daily indacaterol 75 µg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect. International Journal of COPD. 9. 919–919.
18.
Feldman, Gregory, Thomas M. Siler, Damon Jack, et al.. (2010). Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulmonary Medicine. 10(1). 11–11. 101 indexed citations
19.
Feldman, Gregory, et al.. (2009). Efficacy and Safety of Indacaterol 150 µg Once-Daily in COPD: A 12-Week Study.. A4548–A4548. 3 indexed citations
20.
Siler, Thomas M., James E. Swierkosz, Thomas M. Hyers, Alpha A. Fowler, & Robert O. Webster. (1989). Immunoreactive Interleukin-1 in Bronchoalveolar Lavage Fluid of High-Risk Patients and Patients with the Adult Respiratory Distress Syndrome. Experimental Lung Research. 15(6). 881–894. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sümeyye Alparslan Bekir Breakdown of academic impact, for papers by Leon S. Greos Breakdown of academic impact, for papers by Ai Higashi Breakdown of academic impact, for papers by Alison Church Breakdown of academic impact, for papers by Brett Haumann Breakdown of academic impact, for papers by Naveen Kumar Bhatraju Breakdown of academic impact, for papers by Anna Unseld Breakdown of academic impact, for papers by José Pedro Almeida Breakdown of academic impact, for papers by Li-Jun Ma Breakdown of academic impact, for papers by Gabriele Stöhr
Rankless by CCL
2026